1. Scrip
  2. >>Leadership

Ferring's Microbiome Success Based On Much More Than Gut Instinct

No Substitute For Well-Run Trials, Swiss Group's Head Says

 
• By Kevin Grogan

"There's a lot of hope and hype still in the microbiome sphere," Ferring's president Per Falk tells Scrip, but the rewards could be considerable for companies that can deliver well-documented safety and efficacy data and do not take try to take shortcuts.

Per Falk
Ferring president Per Falk backs the potential of microbiome-based therapeutics

Ferring Pharmaceuticals AS president Per Falk has been reflecting on the journey thus far for microbiome-based drugs and why there is no substitute for rigorous clinical data.

Speaking to Scrip hours before the Swiss company unveiled the world’s first positive Phase III results for any microbiome-based therapy with its non-antibiotic RBX2660, Falk gave an insight into how the company has got to the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.